184 related articles for article (PubMed ID: 8611382)
1. Experience with poorly myelosuppressive chemotherapy schedules for advanced myeloma. The Cooperative Group of Study and Treatment of Multiple Myeloma.
Brugnatelli S; Riccardi A; Ucci G; Mora O; Barbarano L; Piva N; Piccinini L; Bergonzi C; De Paoli A; Di Stasi M; Rinaldi E; Trotti G; Petrini M; Ascari E
Br J Cancer; 1996 Mar; 73(6):794-7. PubMed ID: 8611382
[TBL] [Abstract][Full Text] [Related]
2. Comparison of vincristine, carmustine, melphalan, cyclophosphamide, prednisone (VBMCP) and interferon-alpha with melphalan and prednisone (MP) and interferon-alpha (IFN-alpha) in patients with good-prognosis multiple myeloma: a prospective randomized study. Greek Myeloma Study Group.
Zervas K; Pouli A; Gregoraki B; Anagnostopoulos N; Dimopoulos MA; Bourantas K; Tzilianos M; Barbarousi D; Venetis E; Vyniou N; Maniatis A
Eur J Haematol; 2001 Jan; 66(1):18-23. PubMed ID: 11168503
[TBL] [Abstract][Full Text] [Related]
3. Interferon-alpha 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. A randomized, controlled trial. The Nordic Myeloma Study Group.
Ann Intern Med; 1996 Jan; 124(2):212-22. PubMed ID: 8533996
[TBL] [Abstract][Full Text] [Related]
4. Complete remission induction with combined VBMCP chemotherapy and interferon (rIFN alpha 2b) in patients with multiple myeloma.
Oken MM; Kyle RA; Greipp PR; Kay NE; Tsiatis A; Gregory SA; Spiegel R J; O'Connell M J
Leuk Lymphoma; 1996 Feb; 20(5-6):447-52. PubMed ID: 8833401
[TBL] [Abstract][Full Text] [Related]
5. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
Oken MM; Leong T; Lenhard RE; Greipp PR; Kay NE; Van Ness B; Keimowitz RM; Kyle RA
Cancer; 1999 Sep; 86(6):957-68. PubMed ID: 10491521
[TBL] [Abstract][Full Text] [Related]
6. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH
Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039
[TBL] [Abstract][Full Text] [Related]
7. Continuous prednisolone versus conventional prednisolone with VMCP-interferon-alpha2b as first-line chemotherapy in elderly patients with multiple myeloma.
Ludwig H; Spicka I; Klener P; Greil R; Adam Z; Gisslinger H; Tarkovács G; Linkesch W; Maniatis A; Morant R; Drach J; Kuhn I; Schuster J; Hinke A
Br J Haematol; 2005 Nov; 131(3):329-37. PubMed ID: 16225652
[TBL] [Abstract][Full Text] [Related]
8. Interferon-alpha-2b with VMCP for induction in multiple myeloma: the Israel Myeloma Cooperative Group experience.
Cohen AM; Meytes D; Many A; Brenner B; Aghai E; Shaklai M; Kaufman S; Shtalrid M; Attias D; Manor Y
Isr J Med Sci; 1995 Oct; 31(10):604-10. PubMed ID: 7591683
[TBL] [Abstract][Full Text] [Related]
9. Rate of M-component changes and clinical course of 23 responsive myeloma patients.
Riccardi A; Montecucco C; Merlini G; Cremonini N; Danova M; Ascari E
Haematologica; 1984; 69(3):305-14. PubMed ID: 6432642
[No Abstract] [Full Text] [Related]
10. VMCP chemotherapy with or without interferon-alpha-2 in newly diagnosed patients with multiple myeloma.
Preis P; Scheithauer W; Fritz E; Zielinski C; Kuehrer I; Cortelezzi A; Polli E; Baldini L; Pirker R; Kriegisch A
Onkologie; 1989 Feb; 12(1):27-9. PubMed ID: 2654788
[TBL] [Abstract][Full Text] [Related]
11. A new combination chemotherapy for advanced chronic lymphocytic leukemia (vincristine, cyclophosphamide, melphalan, peptichemio, and prednisone protocol).
Ferrara F; Del Vecchio L; Mele G; Rametta V; Ronconi F; Montuori R
Cancer; 1989 Aug; 64(4):789-92. PubMed ID: 2743271
[TBL] [Abstract][Full Text] [Related]
12. [Results of alternating treatment of multiple myeloma--cytostatics VBMCP and recombinant interferon alfa-2B].
Gola A; Usnarska-Zubkiewicz L; Wołowiec D; Urbaniak-Kujda D; Kotlarek-Haus S
Pol Arch Med Wewn; 1993 Aug; 90(2):134-41. PubMed ID: 8247946
[TBL] [Abstract][Full Text] [Related]
13. Treatment of multiple myeloma with an intensive 5-drug combination or intermittent melphalan and prednisone; a randomised multicentre trial. Finnish Leukaemia Group.
Palva IP; Ahrenberg P; Ala-Harja K; Almqvist A; Apajalahti J; Hallman H; Hänninen A; Ilvonen M; Isomaa B; Järvenpää E
Eur J Haematol; 1987 Jan; 38(1):50-4. PubMed ID: 3582605
[TBL] [Abstract][Full Text] [Related]
14. Maintenance treatment with interferon alpha-2b in multiple myeloma: a prospective randomized study from PETHEMA (Program for the Study and Treatment of Hematological Malignancies, Spanish Society of Hematology).
Bladé J; San Miguel JF; Escudero ML; Fontanillas M; Besalduch J; Gardella S; Arias J; García-Conde J; Carnero M; Marti JM; Rozman C; Estapé J; Montserrat E
Leukemia; 1998 Jul; 12(7):1144-8. PubMed ID: 9665202
[TBL] [Abstract][Full Text] [Related]
15. Peptichemio, vincristine, prednisone induction treatment in multiple myeloma.
Merlini G; Riccardi A; Riccardi PG; Montecucco CM; Pavesi F; Ascari E
Tumori; 1985 Dec; 71(6):581-8. PubMed ID: 4082291
[TBL] [Abstract][Full Text] [Related]
16. Phase III study of ranimustine, cyclophosphamide, vincristine, melphalan, and prednisolone (MCNU-COP/MP) versus modified COP/MP in multiple myeloma: a Japan clinical oncology group study, JCOG 9301.
Takenaka T; Itoh K; Suzuki T; Utsunomiya A; Matsuda S; Chou T; Sai T; Sano M; Konda S; Ohno T; Mikuni C; Deura K; Yamada T; Mizorogi F; Nagoshi H; Tomonaga M; Hotta T; Kawano K; Tsushita K; Hirano M; Shimoyama M;
Int J Hematol; 2004 Feb; 79(2):165-73. PubMed ID: 15005346
[TBL] [Abstract][Full Text] [Related]
17. Alternating intravenous courses of melphalan and peptichemio in high-risk multiple myeloma (preliminary results).
Franchi F; Seminara P; Rossi Fanelli F
Anticancer Res; 1986; 6(2):297-8. PubMed ID: 3707066
[TBL] [Abstract][Full Text] [Related]
18. Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients.
Bladé J; San Miguel JF; Alcalá A; Maldonado J; Sanz MA; García-Conde J; Moro MJ; Alonso C; Besalduch J; Zubizarreta A
J Clin Oncol; 1993 Jun; 11(6):1165-71. PubMed ID: 8501503
[TBL] [Abstract][Full Text] [Related]
19. Peptichemio, vincristine and prednisone versus melphalan and prednisone as induction therapy in multiple myeloma.
Riccardi A; Merlini G; Montecucco C; Danova M; Ucci G; Cassano E; Ascari E
Eur J Cancer Clin Oncol; 1986 Jul; 22(7):787-91. PubMed ID: 3770037
[TBL] [Abstract][Full Text] [Related]
20. [Erythropoietin in multiple myeloma].
Pecherstorfer M; Schmoranzer F; Vesely M; Fortelny A; Baumgartner G
Dtsch Med Wochenschr; 1990 Jul; 115(28-29):1096-9. PubMed ID: 2373040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]